|
1
|
Kim ST, Uhm JE, Lee J, et al: Randomized
phase II study of gefitinib versus erlotinib in patients with
advanced non-small cell lung cancer who failed previous
chemotherapy. Lung Cancer. 75:82–88. 2012.
|
|
2
|
Cohen MH, Williams GA, Sridhara R, Chen G
and Pazdur R: FDA drug approval summary: gefitinib (ZD1839)
(Iressa) tablets. Oncologist. 8:303–306. 2003.
|
|
3
|
Perez-Soler R: The role of erlotinib
(Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Clin Cancer Res. 10:4238s–4240s. 2004.
|
|
4
|
de Gramont A and Van Cutsem E:
Investigating the potential of bevacizumab in other indications:
metastatic renal cell, non-small cell lung, pancreatic and breast
cancer. Oncology. 69(Suppl 3): 46–56. 2005.
|
|
5
|
Park S, DiMaio TA, Scheef EA, Sorenson CM
and Sheibani N: PECAM-1 regulates proangiogenic properties of
endothelial cells through modulation of cell-cell and cell-matrix
interactions. Am J Physiol Cell Physiol. 299:C1468–C1484. 2010.
|
|
6
|
Woodfin A, Voisin MB and Nourshargh S:
PECAM-1: a multi-functional molecule in inflammation and vascular
biology. Arterioscler Thromb Vasc Biol. 27:2514–2523. 2007.
|
|
7
|
Bautch VL: VEGF-directed blood vessel
patterning: from cells to organism. Cold Spring Harb Perspect Med.
2:a0064522012.
|
|
8
|
Yang L, Guan H, He J, Zeng L, Yuan Z, Xu
M, Zhang W, Wu X and Guan J: VEGF increases the proliferative
capacity and eNOS/NO levels of endothelial progenitor cells through
the calcineurin/NFAT signalling pathway. Cell Biol Int. 36:21–27.
2012.
|
|
9
|
Holash J, Davis S, Papadopoulos N, et al:
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl
Acad Sci USA. 99:11393–11398. 2002.
|
|
10
|
Ilan N and Madri JA: PECAM-1: old friend,
new partners. Curr Opin Cell Biol. 15:515–524. 2003.
|
|
11
|
Watt SM, Gschmeissner SE and Bates PA:
PECAM-1: its expression and function as a cell adhesion molecule on
hemopoietic and endothelial cells. Leuk Lymphoma. 17:229–244.
1995.
|
|
12
|
Müller AM, Hermanns MI, Skrzynski C,
Nesslinger M, Müller KM and Kirkpatrick CJ: Expression of the
endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro.
Exp Mol Pathol. 72:221–229. 2002.
|
|
13
|
DeLisser HM, Christofidou-Solomidou M,
Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda
C, Merwin JR, Madri JA and Albelda SM: Involvement of endothelial
PECAM-1/CD31 in angiogenesis. Am J Pathol. 151:671–677. 1997.
|
|
14
|
Zhou Z, Christofidou-Solomidou M, Garlanda
C and DeLisser HM: Antibody against murine PECAM-1 inhibits tumor
angiogenesis in mice. Angiogenesis. 3:181–188. 1999.
|
|
15
|
Tachezy M, Reichelt U, Melenberg T,
Gebauer F, Izbicki JR and Kaifi JT: Angiogenesis index CD105
(endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and
proliferation in intraductal papillary mucinous neoplasm (IPMN) of
the pancreas. Histol Histopathol. 25:1239–1246. 2010.
|
|
16
|
Herbst RS, Ansari R, Bustin F, et al:
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in
advanced non-small-cell lung cancer after failure of standard
first-line chemotherapy (BeTa): a double-blind, placebo-controlled,
phase 3 trial. Lancet. 377:1846–1854. 2011.
|
|
17
|
Prager GW, Lackner EM, Krauth MT, et al:
Targeting of VEGF-dependent transendothelial migration of cancer
cells by bevacizumab. Mol Oncol. 4:150–160. 2010.
|
|
18
|
Inai T, Mancuso M, Hashizume H, et al:
Inhibition of vascular endothelial growth factor (VEGF) signaling
in cancer causes loss of endothelial fenestrations, regression of
tumor vessels, and appearance of basement membrane ghosts. Am J
Pathol. 165:35–52. 2004.
|
|
19
|
Lagnien-Gaume V, Jehl J, Manzoni P, et al:
Bevacizumab and lung cancer: eligible patients in daily practice.
Rev Mal Respir. 28:25–31. 2011.(In French).
|
|
20
|
Soutschek J, Akinc A, Bramlage B, et al:
Therapeutic silencing of an endogenous gene by systemic
administration of modified siRNAs. Nature. 432:173–178. 2004.
|
|
21
|
Chien PY, Wang J, Carbonaro D, et al:
Novel cationic cardiolipin analogue-based liposome for efficient
DNA and small interfering RNA delivery in vitro and in vivo. Cancer
Gene Ther. 12:321–328. 2005.
|
|
22
|
Aleku M, Schulz P, Keil O, et al: Atu027,
a liposomal small interfering RNA formulation targeting protein
kinase N3, inhibits cancer progression. Cancer Res. 68:9788–9798.
2008.
|
|
23
|
Czauderna F, Fechtner M, Dames S, et al:
Structural variations and stabilising modifications of synthetic
siRNAs in mammalian cells. Nucleic Acids Res. 31:2705–2716.
2003.
|
|
24
|
Ouyang JS, Li YP, Li CY, et al:
Mitochondrial ROS-K+ channel signaling pathway regulated secretion
of human pulmonary artery endothelial cells. Free Radic Res.
46:1437–1445. 2012.
|
|
25
|
Bidwell GL III, Perkins E and Raucher D: A
thermally targeted c-Myc inhibitory polypeptide inhibits breast
tumor growth. Cancer Lett. 319:136–143. 2012.
|
|
26
|
Feng D, Nagy JA, Pyne K, Dvorak HF and
Dvorak AM: Ultrastructural localization of platelet endothelial
cell adhesion molecule (PECAM-1, CD31) in vascular endothelium. J
Histochem Cytochem. 52:87–101. 2004.
|
|
27
|
Dimaio TA, Wang S, Huang Q, Scheef EA,
Sorenson CM and Sheibani N: Attenuation of retinal vascular
development and neovascularization in PECAM-1-deficient mice. Dev
Biol. 315:72–88. 2008.
|
|
28
|
DeLisser H, Liu Y, Desprez PY, et al:
Vascular endothelial platelet endothelial cell adhesion molecule 1
(PECAM-1) regulates advanced metastatic progression. Proc Natl Acad
Sci USA. 107:18616–18621. 2010.
|
|
29
|
Delisser HM: Targeting PECAM-1 for
anti-cancer therapy. Cancer Biol Ther. 6:121–122. 2007.
|
|
30
|
Aleku M, Fisch G, Möpert K, Keil O, Arnold
W, Kaufmann J and Santel A: Intracellular localization of
lipoplexed siRNA in vascular endothelial cells of different mouse
tissues. Microvasc Res. 76:31–41. 2008.
|
|
31
|
Newman PJ and Newman DK: Signal
transduction pathways mediated by PECAM-1: new roles for an old
molecule in platelet and vascular cell biology. Arterioscler Thromb
Vasc Biol. 23:953–964. 2003.
|
|
32
|
Ilan N, Mahooti S, Rimm DL and Madri JA:
PECAM-1 (CD31) functions as a reservoir for and a modulator of
tyrosine-phosphorylated beta-catenin. J Cell Sci. 112:3005–3014.
1999.
|
|
33
|
Wang Y and Sheibani N: PECAM-1
isoform-specific activation of MAPK/ERKs and small GTPases:
implications in inflammation and angiogenesis. J Cell Biochem.
98:451–468. 2006.
|
|
34
|
Masuda M, Kogata N and Mochizuki N:
Crucial roles of PECAM-1 in shear stress sensing of vascular
endothelial cells. Nihon Yakurigaku Zasshi. 124:311–318. 2004.(In
Japanese).
|
|
35
|
Fujiwara K, Masuda M, Osawa M, Kano Y and
Katoh K: Is PECAM-1 a mechanoresponsive molecule? Cell Struct
Funct. 26:11–17. 2001.
|
|
36
|
Limaye V, Li X, Hahn C, Xia P, Berndt MC,
Vadas MA and Gamble JR: Sphingosine kinase-1 enhances endothelial
cell survival through a PECAM-1-dependent activation of PI-3K/Akt
and regulation of Bcl-2 family members. Blood. 105:3169–3177.
2005.
|
|
37
|
Bergom C, Goel R, Paddock C, Gao C, Newman
DK, Matsuyama S and Newman PJ: The cell-adhesion and signaling
molecule PECAM-1 is a molecular mediator of resistance to genotoxic
chemotherapy. Cancer Biol Ther. 5:1699–1707. 2006.
|
|
38
|
Wu N, Kurosu T, Oshikawa G, Nagao T and
Miura O: PECAM-1 is involved in BCR/ABL signaling and may
downregulate imatinib-induced apoptosis of Philadelphia
chromosome-positive leukemia cells. Int J Oncol. 42:419–428.
2013.
|
|
39
|
Masuda M, Osawa M, Shigematsu H, Harada N
and Fujiwara K: Platelet endothelial cell adhesion molecule-1 is a
major SH-PTP2 binding protein in vascular endothelial cells. FEBS
Lett. 408:331–336. 1997.
|
|
40
|
Enciso JM, Gratzinger D, Camenisch TD,
Canosa S, Pinter E and Madri JA: Elevated glucose inhibits
VEGF-A-mediated endocardial cushion formation: modulation by
PECAM-1 and MMP-2. J Cell Biol. 160:605–615. 2003.
|
|
41
|
Privratsky JR, Tilkens SB, Newman DK and
Newman PJ: PECAM-1 dampens cytokine levels during LPS-induced
endotoxemia by regulating leukocyte trafficking. Life Sci.
90:177–184. 2012.
|
